Australian Prescriber

Concerns have been raised about the potential risk of neurodevelopmental disorders in children of males taking valproate. This article clarifies the place of valproate in clinical practice and discusses the benefits and risks of valproate, particularly for people of childbearing potential.

Emergency contraception methods include oral levonorgestrel, oral ulipristal acetate and the copper intrauterine device. This article outlines the different options, patient factors that guide selection, and key considerations when counselling patients.

Irritable bowel syndrome (IBS) is a common condition, characterised by recurrent abdominal pain or discomfort that is associated with defaecation or a change in bowel habits. This article provides an overview of the diagnosis and management of IBS.

One in 7 Australians is taking an antidepressant, and around half are long-term users. Unnecessarily prolonged antidepressant use should be avoided because of the risk of adverse effects. This article outlines when and how to stop antidepressant medicines.

In April 2026, the PBS (Pharmaceutical Benefits Scheme) restrictions were changed to allow fixed-dose combinations of dual antihypertensive therapy to be prescribed as first-line treatment for adults with hypertension.

Bulevirtide is the first treatment approved for hepatitis D infection in Australia. It blocks the entry of hepatitis B and D viruses into liver cells, thereby preventing viral replication and reducing inflammation and associated liver damage.

Capivasertib is approved for adults HR-positive, HER2-negative advanced breast cancer after disease recurrence or progression with endocrine therapies. It should be used in combination with fulvestrant.

Eflornithine (also known as DFMO) provides an additional treatment option that may improve survival for patients with high-risk neuroblastoma who have at least partially responded to induction and consolidation therapies, including immunotherapy.